Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

GIP and glucagon. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. Tirzepatide, the active ingredient in Eli Lilly's weight loss ...